Cargando…

Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements

PURPOSE: Inverse planning simulated annealing (IPSA) optimized brachytherapy treatment plans are characterized with large isolated dwell times at the first or last dwell position of each catheter. The potential of catheter shifts relative to the target and organs at risk in these plans may lead to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Poder, Joel, Whitaker, May
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965496/
https://www.ncbi.nlm.nih.gov/pubmed/27504129
http://dx.doi.org/10.5114/jcb.2016.60499
_version_ 1782445265342431232
author Poder, Joel
Whitaker, May
author_facet Poder, Joel
Whitaker, May
author_sort Poder, Joel
collection PubMed
description PURPOSE: Inverse planning simulated annealing (IPSA) optimized brachytherapy treatment plans are characterized with large isolated dwell times at the first or last dwell position of each catheter. The potential of catheter shifts relative to the target and organs at risk in these plans may lead to a more significant change in delivered dose to the volumes of interest relative to plans with more uniform dwell times. MATERIAL AND METHODS: This study aims to determine if the Nucletron Oncentra dwell time deviation constraint (DTDC) parameter can be optimized to improve the robustness of high-dose-rate (HDR) prostate brachytherapy plans to catheter displacements. A set of 10 clinically acceptable prostate plans were re-optimized with a DTDC parameter of 0 and 0.4. For each plan, catheter displacements of 3, 7, and 14 mm were retrospectively applied and the change in dose volume histogram (DVH) indices and conformity indices analyzed. RESULTS: The robustness of clinically acceptable prostate plans to catheter displacements in the caudal direction was found to be dependent on the DTDC parameter. A DTDC value of 0 improves the robustness of planning target volume (PTV) coverage to catheter displacements, whereas a DTDC value of 0.4 improves the robustness of the plans to changes in hotspots. CONCLUSIONS: The results indicate that if used in conjunction with a pre-treatment catheter displacement correction protocol and a tolerance of 3 mm, a DTDC value of 0.4 may produce clinically superior plans. However, the effect of the DTDC parameter in plan robustness was not observed to be as strong as initially suspected.
format Online
Article
Text
id pubmed-4965496
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-49654962016-08-08 Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements Poder, Joel Whitaker, May J Contemp Brachytherapy Original Paper PURPOSE: Inverse planning simulated annealing (IPSA) optimized brachytherapy treatment plans are characterized with large isolated dwell times at the first or last dwell position of each catheter. The potential of catheter shifts relative to the target and organs at risk in these plans may lead to a more significant change in delivered dose to the volumes of interest relative to plans with more uniform dwell times. MATERIAL AND METHODS: This study aims to determine if the Nucletron Oncentra dwell time deviation constraint (DTDC) parameter can be optimized to improve the robustness of high-dose-rate (HDR) prostate brachytherapy plans to catheter displacements. A set of 10 clinically acceptable prostate plans were re-optimized with a DTDC parameter of 0 and 0.4. For each plan, catheter displacements of 3, 7, and 14 mm were retrospectively applied and the change in dose volume histogram (DVH) indices and conformity indices analyzed. RESULTS: The robustness of clinically acceptable prostate plans to catheter displacements in the caudal direction was found to be dependent on the DTDC parameter. A DTDC value of 0 improves the robustness of planning target volume (PTV) coverage to catheter displacements, whereas a DTDC value of 0.4 improves the robustness of the plans to changes in hotspots. CONCLUSIONS: The results indicate that if used in conjunction with a pre-treatment catheter displacement correction protocol and a tolerance of 3 mm, a DTDC value of 0.4 may produce clinically superior plans. However, the effect of the DTDC parameter in plan robustness was not observed to be as strong as initially suspected. Termedia Publishing House 2016-06-13 2016-06 /pmc/articles/PMC4965496/ /pubmed/27504129 http://dx.doi.org/10.5114/jcb.2016.60499 Text en Copyright © 2016 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Poder, Joel
Whitaker, May
Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements
title Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements
title_full Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements
title_fullStr Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements
title_full_unstemmed Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements
title_short Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements
title_sort robustness of ipsa optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965496/
https://www.ncbi.nlm.nih.gov/pubmed/27504129
http://dx.doi.org/10.5114/jcb.2016.60499
work_keys_str_mv AT poderjoel robustnessofipsaoptimizedhighdoserateprostatebrachytherapytreatmentplanstocatheterdisplacements
AT whitakermay robustnessofipsaoptimizedhighdoserateprostatebrachytherapytreatmentplanstocatheterdisplacements